Lupin gets USFDA nod to generic version of Prozac tablets

The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.

New Delhi: Drug maker Lupin Tuesday said it has received approval from the US health regulator to market Fluoxetine Tablets, used to treat the major depressive disorder, in the American market.

The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.

Also Read: Lupin receives USFDA approval for Testosterone Gel

The product is also indicated for the treatment of the obsessive-compulsive disorder, Bulimia Nervosa and panic disorder, it said.

Obsessive-compulsive disorder (OCD) is a mental disorder in which a person feels the need to perform certain routines repeatedly (called "compulsions"), or has certain thoughts repeatedly (called "obsessions"). The person is unable to control either the thoughts or activities for more than a short period of time.

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Also Read: Lupin launches antidepressant drug Fluoxetine in the US market